Brain-Acting Ghrelin Protects Gut from Inflammation via Vagus Nerve
Background
The integrity of the intestinal barrier is crucial for health, with its disruption, known as colonic hyperpermeability or 'leaky gut,' implicated in various inflammatory conditions like inflammatory bowel disease (IBD). Lipopolysaccharide (LPS), a component of bacterial cell walls, is a potent trigger for this hyperpermeability and systemic inflammation. While ghrelin, a 'hunger hormone,' is known for its metabolic roles, the specific mechanism by which ghrelin acting in the brain influences gut barrier function in response to inflammatory challenges remained unclear.
Results
The study found that central ghrelin administration significantly mitigated LPS-induced colonic hyperpermeability. Rats treated with ICV ghrelin showed a remarkable 45% reduction (p<0.01) in FITC-dextran translocation compared to LPS-only controls, indicating improved gut barrier function. This protective effect was completely abolished in rats that underwent vagotomy, demonstrating a critical role for the vagus nerve in mediating ghrelin's central actions on the gut. Furthermore, ghrelin treatment restored the expression of key tight junction proteins, such as occludin and ZO-1, which were significantly downregulated by LPS, leading to a 2.3-fold increase in their levels compared to LPS-treated controls. The beneficial effects of ghrelin were also blocked by pre-treatment with a ghrelin receptor antagonist, confirming receptor specificity. Intracerebroventricular ghrelin administration reduced LPS-induced colonic hyperpermeability by a remarkable 45% (p<0.01), restoring gut barrier integrity through a vagus nerve-mediated pathway.
Why It Matters
This research highlights a novel neuro-gastrointestinal pathway where central ghrelin signaling can protect the gut barrier from inflammatory insults. The findings suggest that targeting ghrelin receptors in the brain could be a promising therapeutic strategy for conditions characterized by colonic hyperpermeability, such as inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), or other forms of 'leaky gut' syndrome. This approach offers the potential for a non-invasive method to restore gut barrier integrity, potentially reducing systemic inflammation and improving patient outcomes. Further research, including human clinical trials, is warranted to explore the efficacy and safety of ghrelin-based therapies in patients with these conditions.